Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model (Englisch)
- Neue Suche nach: Vera-Llonch, M.
- Neue Suche nach: Delea, T. E.
- Neue Suche nach: Richardson, E.
- Neue Suche nach: Rupnow, M.
- Neue Suche nach: Grogg, A.
- Neue Suche nach: Oster, G.
- Neue Suche nach: Vera-Llonch, M.
- Neue Suche nach: Delea, T. E.
- Neue Suche nach: Richardson, E.
- Neue Suche nach: Rupnow, M.
- Neue Suche nach: Grogg, A.
- Neue Suche nach: Oster, G.
In:
VALUE IN HEALTH
;
7
, 5
;
569-584
;
2004
-
ISSN:
- Aufsatz (Zeitschrift) / Print
-
Titel:Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov Model
-
Beteiligte:Vera-Llonch, M. ( Autor:in ) / Delea, T. E. ( Autor:in ) / Richardson, E. ( Autor:in ) / Rupnow, M. ( Autor:in ) / Grogg, A. ( Autor:in ) / Oster, G. ( Autor:in )
-
Erschienen in:VALUE IN HEALTH ; 7, 5 ; 569-584
-
Verlag:
- Neue Suche nach: Blackwell Publishing Ltd
-
Erscheinungsdatum:01.01.2004
-
Format / Umfang:16 pages
-
ISSN:
-
Medientyp:Aufsatz (Zeitschrift)
-
Format:Print
-
Sprache:Englisch
- Neue Suche nach: 610
- Weitere Informationen zu Dewey Decimal Classification
-
Klassifikation:
DDC: 610 -
Datenquelle:
© Metadata Copyright the British Library Board and other contributors. All rights reserved.
Inhaltsverzeichnis – Band 7, Ausgabe 5
Zeige alle Jahrgänge und Ausgaben
Die Inhaltsverzeichnisse werden automatisch erzeugt und basieren auf den im Index des TIB-Portals verfügbaren Einzelnachweisen der enthaltenen Beiträge. Die Anzeige der Inhaltsverzeichnisse kann daher unvollständig oder lückenhaft sein.
- 515
-
Publication of Pharmacoeconomic Data Submitted to Reimbursement or Clinical Guidelines AgenciesMauskopf, J. / Drummond, M. et al. | 2004
- 517
-
Technology, Regulations, and Value in HealthLapuerta, P. et al. | 2004
- 518
-
Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?Eichler, H. G. / Kong, S. X. / Gerth, W. C. / Mavros, P. / Jonsson, B. et al. | 2004
- 529
-
Use of Outcomes Research in Assuring Patient Safety and Quality Care, Second Plenary Session, ISPOR 8th Annual International Meeting, Arlington, VA, USAMcClellan, M. B. et al. | 2004
- 535
-
Return on Investment of Different Combinations of Bupropion SR Dose and Behavioral Treatment for Smoking Cessation in a Health Care Setting: An Employer's PerspectiveJavitz, H. S. / Swan, G. E. / Zbikowski, S. M. / Curry, S. J. / McAfee, T. A. / Decker, D. / Patterson, R. / Jack, L. M. et al. | 2004
- 544
-
Medical Care Costs Associated with Postmenopausal Estrogen Plus Progestogen TherapyOhsfeldt, R. L. / Gavin, N. I. / Thorp, J. M. et al. | 2004
- 554
-
Cost-Effectiveness of Interferon Beta-1a, Interferon Beta-1b, and Glatiramer Acetate in Newly Diagnosed Non-primary Progressive Multiple SclerosisProsser, L. A. / Kuntz, K. M. / Bar-Or, A. / Weinstein, M. C. et al. | 2004
- 569
-
Outcomes and Costs of Risperidone versus Olanzapine in Patients with Chronic Schizophrenia or Schizoaffective Disorders: A Markov ModelVera-Llonch, M. / Delea, T. E. / Richardson, E. / Rupnow, M. / Grogg, A. / Oster, G. et al. | 2004
- 585
-
Comparing Medications in a Therapeutic Area Using an NNT ModelCaro, J. J. / Ishak, K. J. / Caro, I. / Migliaccio-Walle, K. / Klittich, W. S. et al. | 2004
- 595
-
Portfolio Theory and Cost-Effectiveness Analysis: A Further DiscussionSendi, P. / Al, M. J. / Rutten, F. F. et al. | 2004
- 602
-
Comparison of the HUI3 with the SF-36 Preference Based SF-6D in a Clinical Trial SettingHatoum, H. T. / Brazier, J. E. / Akhras, K. S. et al. | 2004
- 610
-
Systematic Assessment of Decision Models in Parkinson's DiseaseSiebert, U. / Bornschein, B. / Walbert, T. / Dodel, R. C. et al. | 2004
- 627
-
Estimating Survival for Cost-Effectiveness Analyses: A Case Study in AtherothrombosisCaro, J. J. / Ishak, K. J. / Migliaccio-Walle, K. et al. | 2004